title: Evaluation of drug efficacy in vitro using human small cell carcinoma of the lung spheroids.
abstract: Five human small cell carcinoma of the lung (SCCL) cell lines selected from 25 established cultures were grown as three-dimensional spheroid tumor models in either spinner culture or in static, agar-coated multiwells. Volume doubling times for the cell lines were approximately 4.5 days. Decreases in spheroid volumes after exposure to a variety of chemotherapeutic agents were used as indicators of drug activity. To further quantify cell killing in SCCL spheroids by chemotherapeutic agents 24 hours after exposure to drugs, a technique was employed that measured maximum levels of incorporation of 125IUdR after continuous labeling for 48 hours. The results of the use of this assay report for SCCL spheroid responses to various concentrations of doxorubicin hydrochloride, cytosine arabinoside, mechlorethamine hydrochloride, cisplatin, or etoposide. Some evidence for an intertumor heterogeneous response to chemotherapy is presented for some of the drugs tested. This assay was also used to characterize a potentiated cell kill when etoposide is combined with cisplatin and to identify activity by a new compound, diazoacetylcholine iodide (DACI), which was synthesized as an agent targeted for SCCL cells.
authors.forename: E B
authors.initials: EB
authors.lastname: Douple
authors.forename: C C
authors.initials: CC
authors.lastname: Cate
authors.forename: T J
authors.initials: TJ
authors.lastname: Curphey
authors.forename: O S
authors.initials: OS
authors.lastname: Pettengill
authors.forename: G D
authors.initials: GD
authors.lastname: Sorenson
authors.forename: L H
authors.initials: LH
authors.lastname: Maurer
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002945:Cisplatin / Q000494:pharmacology; D003561:Cytarabine / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D005047:Etoposide / Q000494:pharmacology; D005260:Female; D006801:Humans; D008130:Lomustine / Q000494:pharmacology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008466:Mechlorethamine / Q000494:pharmacology; D051379:Mice; D008815:Mice, Inbred Strains; D010537:Peritoneum; D014410:Tumor Stem Cell Assay
chemical_list: D000970:Antineoplastic Agents; D003561:Cytarabine; D008466:Mechlorethamine; D005047:Etoposide; D008130:Lomustine; D004317:Doxorubicin; D002945:Cisplatin